Detalhe da pesquisa
1.
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
Haematologica
; 104(6): 1202-1208, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30573503
2.
Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
Ann Hematol
; 96(2): 253-259, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27900446
3.
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
Haematologica
; 105(5): 1465, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32358081
4.
Comparison of statistical methods for extrapolating survival in previously untreated diffuse large B-cell lymphoma: results based on the POLARIX study.
J Med Econ
; 26(1): 1178-1189, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37702406
5.
Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial.
Pharmacoecon Open
; 7(1): 37-46, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35900699
6.
Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study.
Clin Lymphoma Myeloma Leuk
; 23(1): 40-48, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36379880
7.
US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.
J Med Econ
; 26(1): 1134-1144, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37674384
8.
Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies.
Oncol Ther
; 9(2): 329-346, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34319556
9.
Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation.
Adv Ther
; 38(7): 3489-3505, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34041708
10.
Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
J Manag Care Spec Pharm
; 27(5): 615-624, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33586513
11.
The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany.
J Comp Eff Res
; 9(14): 1017-1026, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33016109
12.
Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial.
Pharmacoecon Open
; 7(1): 47-48, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36094634
13.
Use of the levonorgestrel-releasing intrauterine system and breast cancer.
Obstet Gynecol
; 106(4): 813-7, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16199640
14.
The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women.
Bone
; 50(4): 965-73, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22289659